| EDUCATIONAL FORUM |
|
| Year : 2015 | Volume
: 47
| Issue : 5 | Page : 479-483 |
TNFerade, an innovative cancer immunotherapeutic
Arunava Kali
Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India
Correspondence Address:
Dr. Arunava Kali
Department of Microbiology, Mahatma Gandhi Medical College and Research Institute, Puducherry
India
 Source of Support: Nil., Conflict of Interest: There are no conflicts of interest.  | Check |
DOI: 10.4103/0253-7613.165190
Tumor necrosis factor-α (TNF-α) is a chemokine with effective tumoricidal properties. However, severe systemic toxicity limits its use of as anticancer agent. TNFerade is a novel replication deficient adenovector based gene therapy, which enables the radiation inducible translation of human TNF-α gene specifically in cancer cells. When injected intratumorally, it has least systemic distribution. Consequently, it lacks TNF-α related systemic toxicity. Evidence suggests that it has superior tumoricidal activity and tolerability with minimum adverse effects. It has demonstrated its beneficial role in the treatment of a variety of cancers in terms of improving the disease free and overall survival, delaying tumor progression, and inducing tumor regression when used with concurrent radiotherapy or chemotherapy.
[FULL TEXT] [PDF]*
|
